Literature DB >> 3123873

Short-term met-hGH infusion inhibits somatotroph response to growth hormone releasing hormone (1-44).

M Rosenbaum1, S Loche, S Balzano, J M Gertner.   

Abstract

To determine whether the short-term administration of growth hormone inhibits pituitary responsiveness to h-GHRH we measured the somatotroph response to h-GHRH-44 (0.3 micrograms/kg) stimulation in ten normal subjects from the third to the fifth hour of an infusion of met-hGH (2 micrograms/kg/h) or saline. Insulin, insulin-like growth factors (IGF), somatomedins, free fatty acids (FFA), glycerol, and glucose levels also were assessed during the first 3 hours of infusion. Steady-state GH levels of 5 to 20 ng/mL were achieved during met-hGH infusion. No significant changes in IGF, insulin, or glucose levels measured at the beginning and again after three hours of infusion occurred within or between conditions. Infusion of met-hGH was associated with a significantly greater increase in FFA levels (69 +/- 50 mumol/L following saline v 433 +/- 57 mumol/L following three hours of met-hGH infusion (P less than .001)). The somatotroph response to h-GHRH-44 was significantly blunted during met-hGH infusion (incremental area under the GH/time curve decreasing from 1,196 +/- 183 (ng/mL) X min to 380 +/- 139 (ng/mL) X min (P less than .005)). These data demonstrate that this blunting can occur following short-term exogenous GH administration and at serum GH levels comparable to those achieved during naturally occurring bursts of GH secretion. They also suggest that acute mediation of GH release must occur, at least in part, at the pituitary somatotroph level and that IGFs and/or insulin may not be the primary inhibitors. This phenomenon may be directly or indirectly due to GH-dependent metabolic factors such as FFA or glycerol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123873     DOI: 10.1016/s0026-0495(98)90006-3

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Effect of a long-term methionyl growth hormone treatment on growth hormone releasing hormone-induced growth hormone secretion in patients with constitutional growth delay.

Authors:  A Sartorio; A Conti; F Morabito; G Faglia
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

2.  The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.

Authors:  J Bellone; S Bellone; G Aimaretti; M R Valetto; C Baffoni; G Corneli; C Origlia; E Arvat; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

3.  GHRH-induced GH responses during recombinant GH treatment in patients with short stature.

Authors:  A Sartorio; A Spada; A Conti; M Monzani; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

4.  Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.

Authors:  A E Pontiroli; R Lanzi; M Monzani; L Musatti; C Guglielmone; G Pozza
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

5.  Galanin infusion restores the blunted GH responses to GHRH administration during GH treatment in children with constitutional growth delay.

Authors:  A Sartorio; A Conti; M Monzani; G Faglia
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

6.  Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Authors:  M Cappa; S Setzu; S Bernardini; D Carta; G Federici; A Grossi; S Loche
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

7.  Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone.

Authors:  I Gil-Ad; B Klinger; A Pertzelan; B Erster; A Silbergeld; H Talpaz; Z Laron
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.